Trial Profile
The Impact of 18F Fluciclovine (FACBC) PET/CT (Positron Emission Computed Tomography) on Management of Patients With Rising PSA (Prostate-specific Antigen) After Initial Prostate Cancer Treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Fluciclovine 18F (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use; Registrational
- Acronyms LOCATE
- Sponsors Blue Earth Diagnostics
- 27 Sep 2021 Post-hoc analysis results published in Blue Earth Diagnostics Media Release.
- 27 Sep 2021 According to an Blue Earth Diagnostics media release, post-hoc analysis of data from the prospective LOCATE and FALCON were presented at the Fifth Global Summit on Precision Diagnosis and Treatment of Prostate Cancer.
- 06 May 2019 According to a Blue Earth Diagnostics media release, data from this trial were presented at the American Urological Association's 2019 Annual Meeting, AUA2019.